Q-omics provides the consensus-scored ZBED5-AS1 profile across patient tissues and cancer cell-line models. ZBED5-AS1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, ZBED5-AS1 is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, ZBED5-AS1 RNA expression shows 18,133 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, KIRP, and TGCT as cancer lineages where ZBED5-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZBED5-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZBED5-AS1 survival associations across molecular data types. ZBED5-AS1 RNA expression shows survival associations in the most cancer types (28). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZBED5-AS1 RNA expression–survival associations across cancer types. High ZBED5-AS1 expression shows unfavorable associations in LAML, but favorable associations in UCEC, KIRP, KIRC, CHOL and MESO. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify UCEC as the clearest survival context for ZBED5-AS1 RNA expression.
This table summarizes ZBED5-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZBED5-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZBED5-AS1 shows lower tumor expression in KIRP, KIRC, KICH, THCA and COAD and higher tumor expression in LIHC. The KIRP box plot shows higher ZBED5-AS1 RNA expression in normal versus tumor tissue (log2 FC = −1.089, t-test p < 0.001).
This table shows molecular features associated with ZBED5-AS1 in patient tissues and cancer cell lines. In patient samples, ZBED5-AS1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
